TransMedics (TMDX) Cash & Equivalents (2018 - 2026)

TransMedics has reported Cash & Equivalents for 9 years, with the latest figure at $472.7 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 18.01% year-over-year to $472.7 million in Q2 2026; TTM through Jun 2026 was $472.7 million, a 18.01% increase from a year earlier, with the FY2025 full-year figure at $488.4 million, up 45.07% from the prior year.
• Cash & Equivalents was $472.7 million for Q2 2026 at TransMedics, up from $461.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $582.2 million in Q2 2023, with the low at $17.9 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $335.2 million, with a median of $356.5 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 1816.05% in 2023, then slumped 37.69% in 2024.
• Over 5 years, Cash & Equivalents stood at $201.2 million in 2022, then soared by 96.25% to $394.8 million in 2023, then retreated by 14.73% to $336.6 million in 2024, then surged by 45.07% to $488.4 million in 2025, then declined by 3.21% to $472.7 million in 2026.
• The last three Cash & Equivalents figures came in at $472.7 million (Q2 2026), $461.7 million (Q1 2026), and $488.4 million (Q4 2025), per Business Quant data.